ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has announced the initiation of a Phase II clinical study for its investigational drug IMM01, an antibody targeting the cluster of differentiation 47 protein (CD47), in combination with a programmed-death 1 (PD-1) inhibitor for the treatment of solid tumors and lymphomas. This marks a significant step forward in the development of IMM01 as a potential immunotherapy option.
Technology and Mechanism
IMM01 was discovered and developed by ImmuneOnco using its proprietary “mAb-Trap” technology platform. The drug’s mechanism of action involves triggering macrophage phagocytosis of tumor cells and presenting phagocytosed tumor antigens to T cells, thereby generating a powerful immunotherapeutic effect. Notably, IMM01 has obtained patents in China, Japan, and the US, highlighting its innovative potential.
Clinical Progress
IMM01 is also undergoing Phase II clinical studies in combination with other agents, including azathioprine (AZA) and PD-1 inhibitors, for the treatment of blood cancers and solid tumors. Over 150 patients have been enrolled in these studies, which have demonstrated a good safety and tolerability profile, alongside encouraging preliminary efficacy results. These findings underscore the potential of IMM01 as a versatile immunotherapy candidate.-Fineline Info & Tech
